Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants - Bosco Paes; Marcello Lanari; Barry Rodgers-Gray; John Fullarton; Xavier Carbonell-Estrany (Frontiers Media S.A., 2024)